[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Implant Resource Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":54},{"warningLetters":4,"total":53},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},985,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-03-25T04:00:00Z\">03\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-12T04:00:00Z\">03\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frex-implants-inc-676429-03122025\">Rex Implants Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Giuseppe Vercellotti\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rex Implants Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>850 Michigan Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Columbus\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:g.vercellotti@reximplants.com\"> g.vercellotti@reximplants.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS#676429\u003C\u002Fp>\u003Cp>March 12, 2025\u003C\u002Fp>\u003Cp>Dear Giuseppe Vercellotti:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Columbus, OH on December 5, 2023, through December 14, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the following devices: the REX Mallet; the rexpander devices; and the PiezoImplant REX BL 2.9 implant system that consists of the REX BL 2.9 implant body, and the Straight, Angled, Healing, Provisional Cylinders, and Multi-Unit abutments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Specifically, these devices are intended to treat an edentulous condition to restore chewing function.\u003C\u002Fp>\u003Cp>FDA has reviewed the information collected during the inspection as well as information on your website at www.reximplants.com; last accessed November 23, 2024, and determined that the devices listed above are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The aforementioned devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>1. Your firm currently has a clearance for the Piezoimplant System, a tissue level blade form endosseous dental implant body and associated dental implant abutments under K211872 for the following indications:\u003C\u002Fp>\u003Cp>The Piezolmplant System is intended for use in dental implant applications for oral rehabilitation of edentulous and partially dentate patients in the maxilla and mandible. Implant retained restorations may consist of single crowns or bridges as well as complete or partial dentures. The prosthetic components are connected to the implants by the corresponding abutments. The Piezolmplant System is intended for delayed loading.\u003C\u002Fp>\u003Cp>The information on your website, demonstrates that the PiezoImplant REX BL 2.9 implant system is currently being marketed for uses that exceed or otherwise differ from your 510(k) clearance in K211872.\u003C\u002Fp>\u003Cp>- The Instructions for Use for the PiezoImplant REX BL 2.9 implant system indicate that if there is implant mobility upon placement, the surgeon has the option to place the implant body deeper, whereas the Instructions for the Piezoimplant System, as cleared in K211872, stated that the implant body should be removed if there is mobility upon placement. This change represents a significantly modified risk. See item A.1.5 of the FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” Placement of the implant body deeper in order to stabilize the implant body implies that the osteotomy has been overprepared – i.e., is too large. The process of placing the implant body deeper is not in line with the standard protocol of splitting the ridge down to the apical aspect of the osteotomy. This change in surgical procedure increases the risk of buccal plate fracture, due to increased bone bending and inferior alveolar nerve damage, leading to permanent nerve damage or sensory loss, if the device is placed too deep in the mandible. Additional concerns include sinus perforation and damage to the maxillary artery, necessitating emergency surgery, if the device is placed too deep in the maxilla. You have not conducted an adequate risk assessment to assess this change.\u003C\u002Fp>\u003Cp>- As cleared in the K211872 submission, the labeling defined that the minimum buccolingual ridge that the Piezoimplant system can be used in is 3.5mm. The information provided in the K211872 submission did not support an indication for placement of the devices in a ridge less than 3.5mm. However, according to the Instructions for Use for the PiezoImplant REX BL 2.9 implant system, the BL implant bodies are intended for placement in ridges that are greater than or equal to 3mm, which constitutes a major change or modification to its intended use. Specifically, the labeling for the REX Piezoimplant BL device system allows for treatment of ridges that measure 3mm buccolingually. The use of the device system in a narrower ridge is a change in patient population, (i.e., a population with a more severely resorbed ridge). See FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” This new patient population includes patients with a buccolingual ridge of less than 3.5mm and presents an increased risk of buccal plate fracture, inferior alveolar nerve damage in the mandible due to proximity of this critical structure, and sinus perforation, with possible damage to the maxillary artery in the maxilla. Patients with limited alveolar bone have less bone available for stable implant placement, and if device failure occurs, will require significant revision surgeries through guided bone regeneration in order to regain lost bony support.\u003C\u002Fp>\u003Cp>- The K211872 clearance described only a tissue level blade-form implant design, with an external hex connection platform, along with abutments compatible with the external hex connection. The PiezoImplant REX BL 2.9 implant system is a bone level design with a different connection platform for attachment of abutment devices, which is a change in technology that could significantly affect the safety or effectiveness of the device. See FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device. The modified risks include an increased risk of implant fracture, requiring additional surgery to retrieve damaged implant parts, restoration failure or fracture, buccal plate fracture leading to loss of osseointegration, and permanent nerve damage. However, you have not conducted an adequate risk assessment to assess this change.\u003C\u002Fp>\u003Cp>2. Based on the evidence obtained from your firm’s website (https:\u002F\u002Fcatalog.reximplants.com), you are offering for sale the following devices: the “rexpanders” and “REX Mallet.” The “REX Mallet” is also called an “Implant Placement Device,” or “IPD.” We have reviewed our files and are unable to identify any FDA clearance or approval for the rexpanders and REX Mallet. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the “rexpanders” and “REX Mallet” are devices because they are intended for use in the mitigation or treatment of disease, i.e., to treat an edentulous condition. Per the Instructions for Use for the Piezoimplant REX BL implant system, and the Instructions for Use for the rexpander devices, the rexpander devices are intended to be used for alveolar ridge splitting including use of force to expand the bone. Per the Instructions for Use for the REX mallet device, this device is intended to exert force in a surgical setting. Therefore, the REX Mallet and rexpanders are devices are used for alveolar ridge splitting, a surgical technique with a significant learning curve to prevent patient harm in the form of buccal plate fracture. Improper use of alveolar ridge splitting can lead to significant patient harm in the form of buccal plate fracture, damage to adjacent teeth, and damage to critical structures such as the inferior alveolar nerve, resulting in the need for revision surgery or permanent nerve damage.\u003C\u002Fp>\u003Cp>3. Based on evidence obtained from your firm’s website (https:\u002F\u002Fcatalog.reximplants.com\u002Fproducts\u002Fcomponents-for-digital-workflow) as of April 3, 2024, your firm is marketing titanium bases intended for use with the REX Piezoimplant TL system. The K211872 submission only included abutments that are not intended to be used with a patient-specific top half. The titanium bases are intended to be used with a patient-specific top half that is cemented to the base. The titanium bases introduce a new biocompatibility concern compared to the devices cleared in the K211872 submission. \u003Cem>See\u003C\u002Fem> item C4 of the FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device.”\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team (EAT) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS Case # 676429\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, EAT Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGiuseppe Vercellotti\n\nRecipient Title\n\nPresident & CEO\n\nRex Implants Inc.\n\n850 Michigan Ave\n\nColumbus, OH 43215\n\nUnited States\n\ng.vercellotti@reximplants.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS#676429\nMarch 12, 2025\nDear Giuseppe Vercellotti:\nDuring an inspection of your firm located in Columbus, OH on December 5, 2023, through December 14, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the following devices: the REX Mallet; the rexpander devices; and the PiezoImplant REX BL 2.9 implant system that consists of the REX BL 2.9 implant body, and the Straight, Angled, Healing, Provisional Cylinders, and Multi-Unit abutments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Specifically, these devices are intended to treat an edentulous condition to restore chewing function.\nFDA has reviewed the information collected during the inspection as well as information on your website at www.reximplants.com; last accessed November 23, 2024, and determined that the devices listed above are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The aforementioned devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n1. Your firm currently has a clearance for the Piezoimplant System, a tissue level blade form endosseous dental implant body and associated dental implant abutments under K211872 for the following indications:\nThe Piezolmplant System is intended for use in dental implant applications for oral rehabilitation of edentulous and partially dentate patients in the maxilla and mandible. Implant retained restorations may consist of single crowns or bridges as well as complete or partial dentures. The prosthetic components are connected to the implants by the corresponding abutments. The Piezolmplant System is intended for delayed loading.\nThe information on your website, demonstrates that the PiezoImplant REX BL 2.9 implant system is currently being marketed for uses that exceed or otherwise differ from your 510(k) clearance in K211872.\n- The Instructions for Use for the PiezoImplant REX BL 2.9 implant system indicate that if there is implant mobility upon placement, the surgeon has the option to place the implant body deeper, whereas the Instructions for the Piezoimplant System, as cleared in K211872, stated that the implant body should be removed if there is mobility upon placement. This change represents a significantly modified risk. See item A.1.5 of the FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” Placement of the implant body deeper in order to stabilize the implant body implies that the osteotomy has been overprepared – i.e., is too large. The process of placing the implant body deeper is not in line with the standard protocol of splitting the ridge down to the apical aspect of the osteotomy. This change in surgical procedure increases the risk of buccal plate fracture, due to increased bone bending and inferior alveolar nerve damage, leading to permanent nerve damage or sensory loss, if the device is placed too deep in the mandible. Additional concerns include sinus perforation and damage to the maxillary artery, necessitating emergency surgery, if the device is placed too deep in the maxilla. You have not conducted an adequate risk assessment to assess this change.\n- As cleared in the K211872 submission, the labeling defined that the minimum buccolingual ridge that the Piezoimplant system can be used in is 3.5mm. The information provided in the K211872 submission did not support an indication for placement of the devices in a ridge less than 3.5mm. However, according to the Instructions for Use for the PiezoImplant REX BL 2.9 implant system, the BL implant bodies are intended for placement in ridges that are greater than or equal to 3mm, which constitutes a major change or modification to its intended use. Specifically, the labeling for the REX Piezoimplant BL device system allows for treatment of ridges that measure 3mm buccolingually. The use of the device system in a narrower ridge is a change in patient population, (i.e., a population with a more severely resorbed ridge). See FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” This new patient population includes patients with a buccolingual ridge of less than 3.5mm and presents an increased risk of buccal plate fracture, inferior alveolar nerve damage in the mandible due to proximity of this critical structure, and sinus perforation, with possible damage to the maxillary artery in the maxilla. Patients with limited alveolar bone have less bone available for stable implant placement, and if device failure occurs, will require significant revision surgeries through guided bone regeneration in order to regain lost bony support.\n- The K211872 clearance described only a tissue level blade-form implant design, with an external hex connection platform, along with abutments compatible with the external hex connection. The PiezoImplant REX BL 2.9 implant system is a bone level design with a different connection platform for attachment of abutment devices, which is a change in technology that could significantly affect the safety or effectiveness of the device. See FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device. The modified risks include an increased risk of implant fracture, requiring additional surgery to retrieve damaged implant parts, restoration failure or fracture, buccal plate fracture leading to loss of osseointegration, and permanent nerve damage. However, you have not conducted an adequate risk assessment to assess this change.\n2. Based on the evidence obtained from your firm’s website (https:\u002F\u002Fcatalog.reximplants.com), you are offering for sale the following devices: the “rexpanders” and “REX Mallet.” The “REX Mallet” is also called an “Implant Placement Device,” or “IPD.” We have reviewed our files and are unable to identify any FDA clearance or approval for the rexpanders and REX Mallet. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the “rexpanders” and “REX Mallet” are devices because they are intended for use in the mitigation or treatment of disease, i.e., to treat an edentulous condition. Per the Instructions for Use for the Piezoimplant REX BL implant system, and the Instructions for Use for the rexpander devices, the rexpander devices are intended to be used for alveolar ridge splitting including use of force to expand the bone. Per the Instructions for Use for the REX mallet device, this device is intended to exert force in a surgical setting. Therefore, the REX Mallet and rexpanders are devices are used for alveolar ridge splitting, a surgical technique with a significant learning curve to prevent patient harm in the form of buccal plate fracture. Improper use of alveolar ridge splitting can lead to significant patient harm in the form of buccal plate fracture, damage to adjacent teeth, and damage to critical structures such as the inferior alveolar nerve, resulting in the need for revision surgery or permanent nerve damage.\n3. Based on evidence obtained from your firm’s website (https:\u002F\u002Fcatalog.reximplants.com\u002Fproducts\u002Fcomponents-for-digital-workflow) as of April 3, 2024, your firm is marketing titanium bases intended for use with the REX Piezoimplant TL system. The K211872 submission only included abutments that are not intended to be used with a patient-specific top half. The titanium bases are intended to be used with a patient-specific top half that is cemented to the base. The titanium bases introduce a new biocompatibility concern compared to the devices cleared in the K211872 submission. See item C4 of the FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device.”\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team (EAT) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 676429” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, EAT Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Rex Implants Inc.","rex-implants-inc-676429-03122025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frex-implants-inc-676429-03122025","2026-10-26T08:09:49.322948+00:00","Warning Letter","Issued","2025-03-25","676429","Medical Devices","Giuseppe Vercellotti","2026-08-19T16:55:21.49+00:00","VIA Electronic Mail","2025-03-12",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":49,"recipient_name":50,"body_fetched_at":51,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2164,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-20T05:00:00Z\">01\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fatlantic-management-resources-ltd-dba-claire-ellen-products-642082-01202023\">Atlantic Management Resources LTD dba. Claire Ellen Products\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Roger Salmonson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Atlantic Management Resources LTD dba. Claire Ellen Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>39 Harvey Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Westborough\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01581-3013\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 20, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #642082\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Salmonson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Atlantic Management Resources Ltd. dba. Claire Ellen Products, FEI 3014117482, located at 39 Harvey Lane, Westborough, MA, from July 26, 2022 to August 10, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Atlantic Management Resources Inc., the manufacturing business entity for Atlantic Management Resources LTD, located at the same address, was duly registered with FDA at the time of manufacturing and distributing, as required by section 510 of the FD&amp;C Act and 21 CFR Part 207. With some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States, or that are offered for import into the United States, must be registered with the FDA. Sections 510(b), (c), (d), and (i) of the FD&amp;C Act, 21 U.S.C. 360(b), (c), (d), and (i).\u003C\u002Fp>\n\n\u003Cp>Atlantic Management Resources LTD distributed under its own name and label, drugs that were not duly listed with FDA. Failure to properly list a drug product is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>As per Atlantic Management Resources LTD’s response to FDA, dated November 5, 2022, the firm agreed to cease production and distribution of all drug products, however, all products previously listed with FDA remain listed, and Atlantic Management Resources Inc, the manufacturing business entity located at the same address, renewed its registration on January 9, 2023 with FDA for the 2023 calendar year.\u003C\u002Fp>\n\n\u003Cp>We reviewed your August 17, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish a quality unit (QU) with the responsibilities and authority to oversee the manufacture of your homeopathic drug products.\u003C\u002Fp>\n\n\u003Cp>You stated that your firm does not have any written procedures, including those that govern quality operations. For example, you failed to have written procedures to ensure documented sampling, examination, and testing of components before production. In addition, you failed to establish a program for qualifying suppliers and ensuring that your homeopathic finished drug products are tested prior to release and distribution to the customer.\u003C\u002Fp>\n\n\u003Cp>Quality unit responsibilities include, but are not limited to, approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies.\u003C\u002Fp>\n\n\u003Cp>These, and other basic quality responsibilities, are integral to conducting effective and appropriate oversight for the manufacturing of your drugs.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to store drug products under appropriate conditions of temperature, humidity, and light so that the identity, strength, quality, and purity are not affected (21 CFR 211.142(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to have adequate storage and warehousing of drug products. For example, although a supplier’s certificate of analysis (COA) for a bulk drug stated that the drug is sensitive to heat, sunlight, and moisture, you failed to monitor storage conditions for the drug, including for temperature and humidity. You also acknowledged that there were inadequate storage conditions for drug products, and for your containers and closures. The holding of drug products must be performed under appropriate conditions so that the identity, strength, quality, and purity are not affected.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to have batch and control records that document your manufacturing operations. You stated that there were no batch records and no batch numbers. Batch records are required to capture significant information to assure that your drug products have been manufactured, processed, packed, or held properly.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On November 3, 2022, FDA held a teleconference with you. We recommended you remove any batches of drug product currently in distribution from the U.S. market and also consider ceasing further distribution.\u003C\u002Fp>\n\n\u003Cp>On November 5, 2022, you communicated your firm’s commitment to cease distribution of the drug product on the website, cease production and distribution of all drug products, and consider a voluntary recall all drug products.\u003C\u002Fp>\n\n\u003Cp>On November 21, 2022, you issued a voluntary nationwide recall of all drug products.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production and distribution of all drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, confirm whether you intend to resume manufacture of any drugs at this facility or any other facility in the future. If you plan to resume any manufacturing regulated under the FD&amp;C Act, notify this office prior to resuming your manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34, to assist your firm in meeting drug CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Owner’s Responsibilities\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with a contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s\u003Cbr>\nguidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements \u003C\u002Fem>at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Establishment Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 510(j)(1) of the FD&amp;C Act, 21 U.S.C. 360(j)(1), 21 CFR 207.41, and 21 CFR 207.49(a)(5), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. Atlantic Management Resources LTD distributed under its own name and label, Neuroquell Plus Cream, which was not listed with FDA at the time of manufacturing and distribution. Failure to properly list a drug product is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMPs. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify identify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to Yvette Johnson, Compliance Officer, at Yvette.Johnson@fda.hhs.gov and ORAPHARM1_RESPONSES@fda.hhs.gov. Please identify your response with FEI #3014117482.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u002F District Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I \u002F New Jersey District\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Roger Salmonson\n\nRecipient Title\n\nOwner\n\nAtlantic Management Resources LTD dba. Claire Ellen Products\n\n39 Harvey Lane\n\nWestborough, MA 01581-3013\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nJanuary 20, 2023\n\nWarning Letter #642082\n\nDear Mr. Salmonson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Atlantic Management Resources Ltd. dba. Claire Ellen Products, FEI 3014117482, located at 39 Harvey Lane, Westborough, MA, from July 26, 2022 to August 10, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nAtlantic Management Resources Inc., the manufacturing business entity for Atlantic Management Resources LTD, located at the same address, was duly registered with FDA at the time of manufacturing and distributing, as required by section 510 of the FD&C Act and 21 CFR Part 207. With some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States, or that are offered for import into the United States, must be registered with the FDA. Sections 510(b), (c), (d), and (i) of the FD&C Act, 21 U.S.C. 360(b), (c), (d), and (i).\n\nAtlantic Management Resources LTD distributed under its own name and label, drugs that were not duly listed with FDA. Failure to properly list a drug product is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nAs per Atlantic Management Resources LTD’s response to FDA, dated November 5, 2022, the firm agreed to cease production and distribution of all drug products, however, all products previously listed with FDA remain listed, and Atlantic Management Resources Inc, the manufacturing business entity located at the same address, renewed its registration on January 9, 2023 with FDA for the 2023 calendar year.\n\nWe reviewed your August 17, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\n\nYour firm failed to establish a quality unit (QU) with the responsibilities and authority to oversee the manufacture of your homeopathic drug products.\n\nYou stated that your firm does not have any written procedures, including those that govern quality operations. For example, you failed to have written procedures to ensure documented sampling, examination, and testing of components before production. In addition, you failed to establish a program for qualifying suppliers and ensuring that your homeopathic finished drug products are tested prior to release and distribution to the customer.\n\nQuality unit responsibilities include, but are not limited to, approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies.\n\nThese, and other basic quality responsibilities, are integral to conducting effective and appropriate oversight for the manufacturing of your drugs.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\n2. Your firm failed to store drug products under appropriate conditions of temperature, humidity, and light so that the identity, strength, quality, and purity are not affected (21 CFR 211.142(b)).\n\nYou failed to have adequate storage and warehousing of drug products. For example, although a supplier’s certificate of analysis (COA) for a bulk drug stated that the drug is sensitive to heat, sunlight, and moisture, you failed to monitor storage conditions for the drug, including for temperature and humidity. You also acknowledged that there were inadequate storage conditions for drug products, and for your containers and closures. The holding of drug products must be performed under appropriate conditions so that the identity, strength, quality, and purity are not affected.\n\n3. Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\n\nYour firm failed to have batch and control records that document your manufacturing operations. You stated that there were no batch records and no batch numbers. Batch records are required to capture significant information to assure that your drug products have been manufactured, processed, packed, or held properly.\n\nDrug Production Ceased\n\nOn November 3, 2022, FDA held a teleconference with you. We recommended you remove any batches of drug product currently in distribution from the U.S. market and also consider ceasing further distribution.\n\nOn November 5, 2022, you communicated your firm’s commitment to cease distribution of the drug product on the website, cease production and distribution of all drug products, and consider a voluntary recall all drug products.\n\nOn November 21, 2022, you issued a voluntary nationwide recall of all drug products.\n\nWe acknowledge your commitment to cease production and distribution of all drug products.\n\nIn response to this letter, confirm whether you intend to resume manufacture of any drugs at this facility or any other facility in the future. If you plan to resume any manufacturing regulated under the FD&C Act, notify this office prior to resuming your manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34, to assist your firm in meeting drug CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nOwner’s Responsibilities\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with a contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s\n\nguidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nEstablishment Registration and Drug Listing Violations\n\nUnder section 510(j)(1) of the FD&C Act, 21 U.S.C. 360(j)(1), 21 CFR 207.41, and 21 CFR 207.49(a)(5), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. Atlantic Management Resources LTD distributed under its own name and label, Neuroquell Plus Cream, which was not listed with FDA at the time of manufacturing and distribution. Failure to properly list a drug product is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o).\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMPs. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify identify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to Yvette Johnson, Compliance Officer, at Yvette.Johnson@fda.hhs.gov and ORAPHARM1_RESPONSES@fda.hhs.gov. Please identify your response with FEI #3014117482.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\u002F District Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I \u002F New Jersey District\n\n_______________________________\n\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Atlantic Management Resources LTD dba. Claire Ellen Products","atlantic-management-resources-ltd-dba-claire-ellen-products-642082-01202023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fatlantic-management-resources-ltd-dba-claire-ellen-products-642082-01202023","2026-10-26T08:07:58.799878+00:00","2023-03-14","642082","Drugs","Division of Pharmaceutical Quality Operations I","Mr. Roger Salmonson","2026-08-20T01:11:56.681+00:00","2023-01-20",2,{"510k":55,"classification":56,"enforcement":57,"event":58,"event_backfill":59,"pma":60,"warning_letter":61},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]